Dr. JOHN YOO JOINS BIOMARK ADVISORY TEAM

Vancouver, British Columbia – (November 17th, 2014) –BioMark Diagnostics Inc. (“BioMark”)
(CSE: BUX) is pleased to announce that it has appointed Dr. John Yoo to its clinical advisory
team.
Dr. Yoo is the Professor and Chair, City-Wide Chief, Department of Otolaryngology-Head and
Neck Surgery and Professor in the Department of Oncology at the Schulich School of Medicine
& Dentistry, Western University; Director of the Head and Neck Oncology & Reconstructive
Surgery Program; and the Co-Chair CancerCare Ontario Head and Neck Disease Site Group.
Rashid Ahmed, President and CEO, comments: “We are extremely excited to welcome Dr. Yoo’s
stature into our company. His achievements in the oncology space will be a major asset to
BioMark’s group. Dr. Yoo’s clinical expertise and research experience brings depth and
practicality as we position our technology for the patient care setting.”
“Biological markers are urgently needed to improve early detection, diagnosis and measuring
response to treatment of lung tumours. BioMark’s technology could be a critically important
tool for clinicians” says Dr. Yoo.

Dr. JOHN YOO JOINS BIOMARK ADVISORY TEAM – November 17, 2014

Share this post:
Share on facebook
Share on twitter
Share on linkedin
Share on email
Categories
Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
CSE: BUX
OTC: BMKDF
FSE: 20B
Investors

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.